These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25137243)

  • 21. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
    Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
    Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial.
    Stearns V; Slack R; Greep N; Henry-Tilman R; Osborne M; Bunnell C; Ullmer L; Gallagher A; Cullen J; Gehan E; Hayes DF; Isaacs C
    J Clin Oncol; 2005 Oct; 23(28):6919-30. PubMed ID: 16192581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of citalopram and venlafaxine's role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial.
    Davari-Tanha F; Soleymani-Farsani M; Asadi M; Shariat M; Shirazi M; Hadizadeh H
    Arch Gynecol Obstet; 2016 May; 293(5):1007-13. PubMed ID: 26437957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial.
    Joffe H; Partridge A; Giobbie-Hurder A; Li X; Habin K; Goss P; Winer E; Garber J
    Menopause; 2010; 17(5):908-16. PubMed ID: 20581724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
    Pinkerton JV; Utian WH; Constantine GD; Olivier S; Pickar JH
    Menopause; 2009; 16(6):1116-24. PubMed ID: 19546826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
    Pinkerton JV; Simon J; Panay N; Seitz C; Parke S; Caetano C; Mellinger U; Haseli Mashhadi N; Haberland C; Atanackovic G; Holz C; Mao G; Morrison M; Nisius S; Schaefers M; Zuurman L
    Menopause; 2024 Jun; 31(6):522-529. PubMed ID: 38564691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trial.
    Hattersley G; Harris AG; Simon JA; Constantine GD
    Menopause; 2017 Jan; 24(1):92-99. PubMed ID: 27575546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthetic conjugated estrogens-B and postmenopausal nocturnal vasomotor symptoms: a randomized controlled trial.
    Liu JH; Reape KZ; Hait HI
    Obstet Gynecol; 2012 Jan; 119(1):78-84. PubMed ID: 22183214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
    Speroff L; Gass M; Constantine G; Olivier S;
    Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women.
    Rebar RW; Trabal J; Mortola J
    Climacteric; 2000 Sep; 3(3):176-82. PubMed ID: 11910619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial.
    Cohen LS; Joffe H; Guthrie KA; Ensrud KE; Freeman M; Carpenter JS; Learman LA; Newton KM; Reed SD; Manson JE; Sternfeld B; Caan B; Freeman EW; LaCroix AZ; Tinker LF; Booth-Laforce C; Larson JC; Anderson GL
    Menopause; 2014 Apr; 21(4):347-54. PubMed ID: 23982113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
    Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K
    Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial.
    Caan B; LaCroix AZ; Joffe H; Guthrie KA; Larson JC; Carpenter JS; Cohen LS; Freeman EW; Manson JE; Newton K; Reed S; Rexrode K; Shifren J; Sternfeld B; Ensrud K
    Menopause; 2015 Jun; 22(6):607-15. PubMed ID: 25405571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Critical appraisal of paroxetine for the treatment of vasomotor symptoms.
    Carroll DG; Lisenby KM; Carter TL
    Int J Womens Health; 2015; 7():615-24. PubMed ID: 26124682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.
    Archer DF; Freeman EW; Komm BS; Ryan KA; Yu CR; Mirkin S; Pinkerton JV
    J Womens Health (Larchmt); 2016 Nov; 25(11):1102-1111. PubMed ID: 27676118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing sleep across the menopausal transition.
    Baker FC
    Climacteric; 2023 Jun; 26(3):198-205. PubMed ID: 37011660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.
    Joffe H; Guthrie KA; LaCroix AZ; Reed SD; Ensrud KE; Manson JE; Newton KM; Freeman EW; Anderson GL; Larson JC; Hunt J; Shifren J; Rexrode KM; Caan B; Sternfeld B; Carpenter JS; Cohen L
    JAMA Intern Med; 2014 Jul; 174(7):1058-66. PubMed ID: 24861828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.
    Guthrie KA; LaCroix AZ; Ensrud KE; Joffe H; Newton KM; Reed SD; Caan B; Carpenter JS; Cohen LS; Freeman EW; Larson JC; Manson JE; Rexrode K; Skaar TC; Sternfeld B; Anderson GL
    Obstet Gynecol; 2015 Aug; 126(2):413-422. PubMed ID: 26241433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer.
    Weitzner MA; Moncello J; Jacobsen PB; Minton S
    J Pain Symptom Manage; 2002 Apr; 23(4):337-45. PubMed ID: 11997203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.